Guardant Health, Inc. (GH) |
|
48.22 -1.29 (-2.61%)
|
12-07 16:00 |
|
Open: |
49.09 |
Pre. Close: |
49.51 |
|
High:
|
50.16 |
Low:
|
47.865 |
|
Volume:
|
568,341 |
Market Cap:
|
4,939(M) |
|
|
|
Technical analysis |
as of: 2022-12-07 4:22:35 PM |
|
Overall:
|
 |
| Stoxline posted a STRONG SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 63.62 One year: 74.3 |
| Support: |
Support1: 45.73 Support2: 40.34 |
| Resistance: |
Resistance1: 54.47 Resistance2: 63.62 |
| Pivot: |
50.11  |
| Moving Average: |
MA(5): 51.18 MA(20): 49.77 
MA(100): 50.93 MA(250): 56.98 |
| MACD: |
MACD(12,26): 0.5 Signal(9): 0.4 |
| Stochastic oscillator: |
%K(14,3): 46.9 %D(3): 65.8 |
| RSI: |
RSI(14): 46.6 |
| 52-week: |
High: 103.91 Low: 27.64 |
| Average Vol(K): |
3-Month: 1,014 (K) 10-Days: 602 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ GH ] has closed above bottom band by 25.3%. Bollinger Bands are 34.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
50.27 - 50.57 |
50.57 - 50.79 |
|
Low:
|
47.16 - 47.55 |
47.55 - 47.84 |
|
Close:
|
47.71 - 48.28 |
48.28 - 48.71 |
|
Company Description |
|
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California. |
Headline News |
Wed, 07 Dec 2022
GH's Lindstrom's Book Optioned - Soap Opera Digest
Wed, 07 Dec 2022
GH Spoilers For December 8: Did Danger Track Down Anna And Valentin? - Soap Hub
Wed, 07 Dec 2022
Bond haircut: I have lost over GH¢100,000 – Franklin Cudjoe - GhanaWeb
Wed, 07 Dec 2022
Zac Taylor On Joe Burrow's Personality Mirroring His Team's And More In Bengals.com's Taylor-Made Takes - Bengals.com
Wed, 07 Dec 2022
Bank of Ghana upgrades GH¢1 coin - Pulse Ghana
Tue, 06 Dec 2022
GH Spoilers Speculation: Drew Will End Things Over Carly’s Lie - Soap Hub
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Diagnostics & Research |
| Shares Out. |
102 (M) |
| Shares Float |
98 (M) |
|
% Held by Insiders
|
4.6 (%) |
|
% Held by Institutions
|
94.9 (%) |
|
Shares Short
|
3,990 (K) |
|
Shares Short P.Month
|
3,760 (K) |
Stock Financials |
|
EPS
|
-4.14 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1.62 |
|
Profit Margin (%)
|
-140.6 |
|
Operating Margin (%)
|
-115.3 |
|
Return on Assets (ttm)
|
-15.9 |
|
Return on Equity (ttm)
|
-125.5 |
|
Qtrly Rev. Growth
|
23.8 |
|
Gross Profit (p.s.)
|
2.44 |
|
Sales Per Share
|
4.2 |
|
EBITDA (p.s.)
|
-4.54 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-296 (M) |
|
Levered Free Cash Flow
|
-276 (M) |
Stock Valuations |
|
PE Ratio
|
-11.68 |
|
PEG Ratio
|
-0.7 |
|
Price to Book value
|
29.58 |
|
Price to Sales
|
11.46 |
|
Price to Cash Flow
|
-16.71 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
